Cargando…

Kounis syndrome associated with BNT162b2 mRNA COVID-19 vaccine presenting as ST-elevation acute myocardial infarction

Detalles Bibliográficos
Autores principales:	Şancı, Emre, Örçen, Cihan, Çelik, Osman Muhsin, Özen, Muhammed Tahsin, Bozyel, Serdar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Turkish Society of Cardiology 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878946/ https://www.ncbi.nlm.nih.gov/pubmed/35191390 http://dx.doi.org/10.5152/AnatolJCardiol.2021.1212

Ejemplares similares

Kounis syndrome: ST elevations in the setting of anaphylaxis
por: Cesarz, Taylor, et al.
Publicado: (2023)

Kounis Syndrome: Dexketoprofen-Associated ST-Elevation Myocardial Infarction
por: Aksakal, Aytekin, et al.
Publicado: (2021)

Successful Treatment of Kounis Syndrome Type I Presenting as Cardiac Arrest with ST Elevation
por: Oh, Kie Young, et al.
Publicado: (2016)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

An Acute Adverse Reaction with ST Elevation Induced by Magnetic Resonance Contrast Media: Kounis Syndrome
por: Tanaka, Hiroki, et al.
Publicado: (2018)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

BNT162b2 mRNA COVID-19 Vaccine: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
por: Terashima, Takeshi
Publicado: (2021)

Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
por: Gouda, Wesam, et al.
Publicado: (2022)

Central serous chorioretinopathy following the BNT162b2 mRNA vaccine
por: Hanhart, J., et al.
Publicado: (2022)

Addendum: Systems vaccinology of the BNT162b2 mRNA vaccine in humans
por: Arunachalam, Prabhu S., et al.
Publicado: (2023)

Antibody response after a booster dose of BNT162B2mRNA and inactivated COVID-19 vaccine
por: Yigit, Metin, et al.
Publicado: (2022)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
por: Cocomazzi, Giovanna, et al.
Publicado: (2021)

Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
por: Felices-Farias, Jose Manuel, et al.
Publicado: (2022)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
por: Payne, Rebecca P., et al.
Publicado: (2021)

Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans
por: Dickerman, Barbra A., et al.
Publicado: (2021)

What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
por: Silvestris, Nicola
Publicado: (2021)

Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
por: June Choe, Young, et al.
Publicado: (2022)

Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
por: Felices-Farias, Jose Manuel, et al.
Publicado: (2022)

Hemophagocytic Lymphohistiocytosis Following BNT162b2 mRNA COVID-19 Vaccination
por: Lin, Ting-Yu, et al.
Publicado: (2022)

Erythema nodosum triggered by BNT162b2 mRNA COVID-19 vaccine
por: Juddoo, Vanessa, et al.
Publicado: (2022)

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
por: Thompson, Mark G., et al.
Publicado: (2021)

Systems biological assessment of human immunity to BNT162b2 mRNA vaccination
por: Arunachalam, Prabhu S., et al.
Publicado: (2021)

Pericarditis after administration of the BNT162b2 mRNA COVID-19 vaccine
por: Ramírez-García, Almudena, et al.
Publicado: (2021)

BNT162b2 mRNA Vaccine Interference with Co-Administration of Tdap Vaccine
por: Chilimuri, Sridhar, et al.
Publicado: (2021)

Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents
por: Mansanguan, Suyanee, et al.
Publicado: (2022)

Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability
por: Graydon, Elizabeth K., et al.
Publicado: (2023)

Myopericarditis After BNT162b2 mRNA Vaccination With Incidental Intramyocardial Bridging
por: Elghazal, Mohamed, et al.
Publicado: (2023)

Acute Myocarditis or the Kounis Syndrome: Role of Cardiac MRI and Speckle-Tracking Echocardiography in Diagnosis
por: Karaca, Oguz, et al.
Publicado: (2014)

Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
por: Kitagawa, Hiroki, et al.
Publicado: (2022)

Pronounced antibody elevation after SARS‐CoV‐2 BNT162b2 mRNA booster vaccination in nursing home residents
por: Chong, Yong, et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

BNT162b2, mRNA-1273, et EMA : une procédure qui roule
por: Dalmat, Yann-Mickael
Publicado: (2021)

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Barda, Noam, et al.
Publicado: (2021)

The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273
por: Markewitz, Robert, et al.
Publicado: (2022)

BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity
por: Vizcarra, Pilar, et al.
Publicado: (2021)

Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine
por: Saito, Kazuyuki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_espamjgv1po240puq71kpaq5m8